Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
direct-acting antiviral |
| gptkbp:approvedBy |
gptkb:US_Food_and_Drug_Administration
gptkb:European_Medicines_Agency 2014 |
| gptkbp:ATCCode |
J05AP07
|
| gptkbp:brand |
Daklinza
|
| gptkbp:CASNumber |
1009119-64-5
|
| gptkbp:combines |
gptkb:sofosbuvir
|
| gptkbp:developedBy |
2010s
|
| gptkbp:discoveredBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:eliminationHalfLife |
12-15 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C40H50Cl2N8O6
|
| https://www.w3.org/2000/01/rdf-schema#label |
daclatasvir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
NS5A inhibitor
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
B1 (Australia)
N (US) |
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea fatigue headache |
| gptkbp:usedFor |
treatment of hepatitis C
|
| gptkbp:bfsParent |
gptkb:DB09223
|
| gptkbp:bfsLayer |
5
|